Anticancer Drugs PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Anticancer Drugs PDF full book. Access full book title Anticancer Drugs by Niamh M O’Boyle. Download full books in PDF and EPUB format.
Author: Niamh M O’Boyle
Publisher: MDPI
ISBN: 3039215868
Category : Medical
Languages : en
Pages : 214
Get Book Here
Book Description
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
Author: Niamh M O’Boyle
Publisher: MDPI
ISBN: 3039215868
Category : Medical
Languages : en
Pages : 214
Get Book Here
Book Description
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
Author: Gw Sledge
Publisher: Clinical Pub
ISBN: 9781846920660
Category : Breast
Languages : en
Pages : 0
Get Book Here
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Kumar, Sumit
Publisher: IGI Global
ISBN: 1799865312
Category : Medical
Languages : en
Pages : 913
Get Book Here
Book Description
The complexity of cancer demands an integrated approach from both a cancer biology standpoint and a pharmaceutical basis to understand the different anticancer modalities. Current research has been focused on conventional and newer anticancer modalities, recent discoveries in cancer research, and also the advancements in cancer treatment. There is a current need for more research on the advances in cancer therapeutics that bridge the gap between basic research (pharmaceutical drug development processes, regulatory issues, and translational experimentation) and clinical application. Recent promising discoveries such as immunotherapies, promising therapies undergoing clinical trials, synthetic lethality, carbon beam radiation, and other exciting targeted therapies are being studied to improve and advance the studies of modern cancer treatment. The Handbook of Research on Advancements in Cancer Therapeutics serves as a comprehensive guide in modern cancer treatment by combining and merging the knowledge from both cancer biology and the pharmacology of anticancer modalities. The chapters come from multi-disciplinary backgrounds, including scientists and clinicians from both academia and various industries, to discuss nascent personalized therapies and big data-driven cancer treatment. While highlighting topic areas that include cancer prevention, cancer therapeutics, and cancer treatments through the lenses of technology, medicine/drugs, and alternate therapies, this book is ideally intended for oncologists, radiation oncologists, surgical oncologists, and cancer biologists, along with practitioners, stakeholders, researchers, academicians, and students who are interested in understanding the most fundamental aspects of cancer and the available therapeutic opportunities.
Author: Shabir Ahmad Ganai
Publisher: Springer
ISBN: 9811380198
Category : Medical
Languages : en
Pages : 101
Get Book Here
Book Description
This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors’ therapeutic efficacy against various neurological complications.
Author: Shabir Ahmad Ganai
Publisher: Springer Nature
ISBN: 9811581797
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Author: Stephen Safe
Publisher: Frontiers Media SA
ISBN: 2832548482
Category : Medical
Languages : en
Pages : 103
Get Book Here
Book Description
Pancreatic cancer is a highly lethal gastrointestinal disease that is becoming one of the leading causes of cancer mortality worldwide. Despite advances in surgery, radiation therapy, immuno-oncology, and therapeutics, the 5-year survival rate for pancreatic cancer patients remains around 12%. The poor prognosis is mainly due to late diagnosis, as pancreatic cancer patients commonly don’t exhibit symptoms until an advanced stage that is beyond surgical resection. Currently, the main treatments for patients with advanced pancreatic cancer are chemotherapy, radiotherapy, and most recent clinical trials incorporate immunotherapy.
Author: H.-J. Senn
Publisher: Springer Science & Business Media
ISBN: 9783540222286
Category : Medical
Languages : en
Pages : 346
Get Book Here
Book Description
This volume contains the majority of the invited keynote lectures presented by experts at the Third International Conference on Controversies in Tumor Prevention and Genetics on 12-14 February 2004 in St.Gallen, Switzerland. Together, they reveal the latest findings in oncogenetics and its relations to recent and future developments in primary and secondary tumor prevention, especially in breast, colon and lung cancer. All contributions are written and have been critically reviewed by internationally recognised leaders in the field.
Author: Qiao-Hong Chen
Publisher: MDPI
ISBN: 3036501401
Category : Business & Economics
Languages : en
Pages : 606
Get Book Here
Book Description
This book is a printed edition of the Special Issue entitled “Anticancer Agents: Design, Synthesis and Evaluation” that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers.
Author: Xiangpeng Dai
Publisher: Frontiers Media SA
ISBN: 2832536778
Category : Medical
Languages : en
Pages : 147
Get Book Here
Book Description
Author: Lixiang Xue
Publisher: Frontiers Media SA
ISBN: 2832528953
Category : Science
Languages : en
Pages : 152
Get Book Here
Book Description
